FibroGen, Inc. Q3 2025 Earnings Recap

FGEN Q3 2025 November 11, 2025

FibroGen's third quarter 2025 results highlight significant corporate transformations with the successful sale of FibroGen China for $220 million, extending the company's financial runway into 2028 and paving the way for advancing its promising oncology pipeline.

Earnings Per Share Beat

$-1.61 vs $-4.01 est.

+59.9% surprise

Revenue Miss

1076000 vs 1670000 est.

-35.6% surprise

Market Reaction

1-Day -9.64%

5-Day -21.0%

30-Day -23.45%

Key Takeaways

Completed the sale of FibroGen China to AstraZeneca for approximately $220 million, enhancing liquidity and eliminating debt obligations.
Progressed with FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer (mCRPC), initiating a Phase II trial and anticipating key trial results in early 2026.
Clear regulatory pathway established for roxadustat's Phase III trial submission for lower-risk myelodysplastic syndromes, enhancing the company's therapeutic potential.
FG-3246 shows promising early results, with notable radiographic progression-free survival and response rates in heavily pretreated mCRPC patients.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit FGEN on AllInvestView.